Bioventix-BVXP4 Videos

Order By
Bioventix (BVXP) – ShareSoc presentation October 2018
0
33:33

Bioventix (BVXP) ShareSoc presentation October 2018

Bioventix ShareSoc presentation: October 2018 By Peter Harrison, CEO. Includes full year results year ended 30th June 2018. Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing […]
Bioventix (BVXP) Full Year results June 2016 interview
4
21:17

Bioventix (BVXP) Full Year results June 2016 interview

Length: c 20 mins Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange. He goes on to talk about the NT proBNP licence, which comes to an end July 2017, […]
Bioventix – BVXP – Company overview
0
07:01

Bioventix – BVXP – Company overview

Introduction to Bioventix (BVXP) by Peter Harrison, CEO Length: c. 6 mins Peter Harrison, CEO, tells us what Bioventix does, and discusses the business model. Essentially BVXP develops antibodies for use in different blood testing machines manufactured by the big names: Roche, Siemens, Abbot, etc. He goes into detail about BVXP antibodies types, and why […]
Bioventix BVXP ShareSoc Richmond 6 6 16
4

Bioventix BVXP ShareSoc Richmond 6 6 16

Peter Harrison CEO Bioventix (BVXP) ShareSoc Richmond 6.6.16 A succinct presentation to understand what BVXP do. • The product • Revenue streams • Stickiness of revenue • Timelines to develop revenue streams • Barriers to entry • Threats • The future A sense of the culture of the company The journey of the historic research […]
Private Investor World content is for general information and interest. It does not constitute any kind of recommendation or inducement to buy shares of any company. Private Investor World is not offering any kind of financial advice, and nothing in our content should be taken as such. For these reasons any Private Investor World content falls outside the scope of FCA regulation.
CLOSE